Literature DB >> 33394263

Cyproterone acetate and meningioma: a nationwide-wide population based study.

Charles Champeaux-Depond1,2, Joconde Weller3, Sebastien Froelich4, Agnes Sartor5.   

Abstract

BACKGROUND: The study the characteristics of surgical meningiomas in female patients who took CPA and to compare this population to a non-CPA control group.
MATERIALS AND METHODS: We processed the French Système National des Données de Santé (SNDS) database to retrieve appropriate cases operated between 2007 and 2017.
RESULTS: 1 101 female patients (3.8%) who used to take CPA and underwent a meningioma surgery were extracted from a nationwide population based cohort of 28 924 patients. Median age at CPA prescription was 42 years IQR[36.7-48.9]. The median time between CPA start and surgery was 5.5 years IQR[3.1-7.9]. The median age at surgery was significantly lower in patients who were treated by CPA (47 years, IQR[42-54) compared to the non-CPA population (61 years, IQR[51-70], p < 0.001). Median CPA dose was 40 g, IQR[19-72]. There was a strong correlation between CPA dose and duration (r = 0.58, 95%CI[0.54-0.62], p < 0.001). Middle skull base was the most common (39%) location with a anterior skull base insertion being also far more common compared to the usual population with 21.9% of the tumour. This skull base predominance of CPA-associated meningioma is highly significant (p < 0.001). Increased CPA dose raised the risk of having multiple meningioma surgeries (p < 0.001) and multiple meningioma locations (p < 0.001). Tumour grading was not modified by CPA treatment (p = 0.603). Benign or grade I meningioma accounting for 92%, atypical or grade II for 6.1% and malignant or grade III for 1.9%.
CONCLUSION: In the past 10 years, a significant number of CPA-induced meningiomas have been removed, modifying the global pyramid of age at surgery for female patients. These tumours occur well before the usual age and are preferentially located on the anterior and middle skull base.

Entities:  

Keywords:  Cyproterone; Epidemiology; Meningioma; Progestin; SNDS

Year:  2021        PMID: 33394263     DOI: 10.1007/s11060-020-03672-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  4 in total

1.  Close follow-up after discontinuation of cyproterone acetate: a possible option to defer surgery in patients with voluminous intracranial meningioma.

Authors:  Fahed Zairi; Rabih Aboukais; Emilie LE Rhun; Paulo Marinho; Claude A Maurage; Jean P Lejeune
Journal:  J Neurosurg Sci       Date:  2017-02       Impact factor: 2.279

2.  Cause-Specific Survival After Meningioma Surgery: A Nationwide Population-Based Competing Risk Study.

Authors:  Charles Champeaux-Depond; Panayotis Constantinou; Joconde Weller
Journal:  World Neurosurg       Date:  2020-10-20       Impact factor: 2.104

Review 3.  Epidemiology of meningiomas.

Authors:  I Baldi; J Engelhardt; C Bonnet; L Bauchet; E Berteaud; A Grüber; H Loiseau
Journal:  Neurochirurgie       Date:  2014-09-22       Impact factor: 1.553

4.  Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment.

Authors:  Sylvain Portet; Rania Naoufal; Gaëlle Tachon; Adrien Simonneau; Anaïs Chalant; Amir Naar; Serge Milin; Benoit Bataille; Lucie Karayan-Tapon
Journal:  Neurooncol Adv       Date:  2019-05-28
  4 in total
  4 in total

1.  Progestin-related WHO grade II meningiomas behavior-a single-institution comparative case series.

Authors:  Antoine Devalckeneer; Rabih Aboukais; Maxime Faisant; Philippe Bourgeois; Vannod-Michel Quentin; Claude-Alain Maurage; Fabienne Escande; Jean-Paul Lejeune
Journal:  Neurosurg Rev       Date:  2021-11-30       Impact factor: 3.042

2.  Meningioma in patients exposed to progestin drugs: results from a real-life screening program.

Authors:  Catherine Oppenheim; Joseph Benzakoun; Thomas Samoyeau; Corentin Provost; Alexandre Roux; Laurence Legrand; Edouard Dezamis; Geneviève Plu-Bureau; Johan Pallud
Journal:  J Neurooncol       Date:  2022-09-06       Impact factor: 4.506

3.  A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas.

Authors:  Keng Siang Lee; John J Y Zhang; Ramez Kirollos; Thomas Santarius; Vincent Diong Weng Nga; Tseng Tsai Yeo
Journal:  Sci Rep       Date:  2022-02-04       Impact factor: 4.379

4.  Association of Hormonal Contraception with Meningioma Location in Indonesian Patients.

Authors:  Rusdy Ghazali Malueka; Rahmat Andi Hartanto; Nurhuda Hendra Setyawan; Dyajeng Noor Firdaus Fauzi; Khoironi Rachmad Damarjati; Alfian Rismawan; Maria Alethea Septianastiti; Adiguno Suryo Wicaksono; Kusumo Dananjoyo; Endro Basuki; Ahmad Asmedi; Ery Kus Dwianingsih
Journal:  Asian Pac J Cancer Prev       Date:  2022-03-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.